[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX9300948A - Un antagonista novedoso del receptor 5ht3 - Google Patents

Un antagonista novedoso del receptor 5ht3

Info

Publication number
MX9300948A
MX9300948A MX9300948A MX9300948A MX9300948A MX 9300948 A MX9300948 A MX 9300948A MX 9300948 A MX9300948 A MX 9300948A MX 9300948 A MX9300948 A MX 9300948A MX 9300948 A MX9300948 A MX 9300948A
Authority
MX
Mexico
Prior art keywords
treatment
receiver
antagonist
novel
novel antagonist
Prior art date
Application number
MX9300948A
Other languages
English (en)
Inventor
Maurice W Gittos
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of MX9300948A publication Critical patent/MX9300948A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se relaciona con el octahidro 3-hidroxi-2,6-metano-2H-qunolizin-8-il éster del ácido 5-cloro-2,3-dihidro-2,2-dimetilbenzofuran-7-carbox ílico, un antagonista novedoso del receptor 5-HT3, con su método de preparación y con su uso final en la aplicación en el tratamiento de las náuseas y el vómito, en el tratamiento del dolor asociado con migraña, en el tratamiento de psicosis endógena alucinatoria del tipo manifestado en pacientes que sufren de esquizofrenia y manía, para el síndrome del intestino inflamatorio o irritable o para combatir el abuso de las drogas.
MX9300948A 1992-02-24 1993-02-22 Un antagonista novedoso del receptor 5ht3 MX9300948A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24

Publications (1)

Publication Number Publication Date
MX9300948A true MX9300948A (es) 1993-08-01

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9300948A MX9300948A (es) 1992-02-24 1993-02-22 Un antagonista novedoso del receptor 5ht3

Country Status (14)

Country Link
EP (1) EP0628043A1 (es)
JP (1) JPH07504192A (es)
KR (1) KR100287933B1 (es)
AU (1) AU675060B2 (es)
CA (1) CA2130563C (es)
FI (1) FI105917B (es)
HU (1) HU216831B (es)
IL (1) IL104821A (es)
MX (1) MX9300948A (es)
NO (1) NO943101D0 (es)
NZ (1) NZ249346A (es)
TW (1) TW226374B (es)
WO (1) WO1993017019A1 (es)
ZA (1) ZA931146B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537255A (ja) 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト リウマチ性炎症性プロセスに対する５−ｈｔ３レセプターアンタゴニストの全身的使用
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
EP1861096B1 (en) 2005-03-07 2018-12-26 The University of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080727T3 (es) * 1988-02-23 1996-02-16 Merrell Pharma Inc Uso de quinolizina y derivados de quinolizinona en la fabricacion de medicamentos.
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
AU3603493A (en) 1993-09-13
AU675060B2 (en) 1997-01-23
FI943872A0 (fi) 1994-08-23
IL104821A0 (en) 1993-06-10
KR950700297A (ko) 1995-01-16
FI105917B (fi) 2000-10-31
EP0628043A1 (en) 1994-12-14
CA2130563A1 (en) 1993-09-02
FI943872A (fi) 1994-08-23
HUT68249A (en) 1995-06-28
WO1993017019A1 (en) 1993-09-02
TW226374B (es) 1994-07-11
NZ249346A (en) 1995-10-26
KR100287933B1 (ko) 2001-05-02
JPH07504192A (ja) 1995-05-11
IL104821A (en) 1997-01-10
CA2130563C (en) 1997-11-11
NO943101L (no) 1994-08-23
ZA931146B (en) 1993-09-14
HU216831B (hu) 1999-09-28
HU9402436D0 (en) 1994-10-28
NO943101D0 (no) 1994-08-23

Similar Documents

Publication Publication Date Title
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
UA27776C2 (uk) Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
EA199900045A1 (ru) Производные спиропиперидина и их использование в качестве терапевтических агентов
BR9609013A (pt) Análogo de nucleosìdeos, e, composto.
MX9300977A (es) Compuetos heterobiciclicos.
MY132229A (en) Indole derivatives as 5-ht receptor antagonist
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
EA199800868A1 (ru) Конденсированные ариламидопиридины и пиримидины, содержащая их фармацевтическая композиция, способ лечения, промежуточные соединения и способ их получения
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
DK0725782T3 (da) A1-adenosin-receptor-agonister og antiagonister
FI935134A0 (fi) Substituerade 3-aminokinuklidiner
NO952398L (no) Pyrrolpyrimidiner som CRF antagonister
ATE254456T1 (de) Cannabinoid-rezeptor-antagonisten
ECSP941156A (es) 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
MX9203320A (es) Composicion antialergica que contiene compuestos biciclicos switterionicos.
DK1019426T3 (da) Hidtil ukendte A1-adenosinreceptoragonister og -antagonister
DE69413535D1 (de) 1-phenylalkanone als 5-ht4 rezeptor ligande
MX9300948A (es) Un antagonista novedoso del receptor 5ht3
ES556864A0 (es) Procedimiento para la obtencion de benzopiranos sustituidos.
EA199800701A1 (ru) БЕНЗО[С]ХИНОЛИЗИНОВЫЕ ПРОИЗВОДНЫЕ, ИХ ПОЛУЧЕНИЕ И ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ 5a-РЕДУКТАЗ
ES2166462T3 (es) Antagonistas del receptor de la endotelina.
MX9302985A (es) Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad.
ZA949545B (en) Bicyclic carboxylic acid leukotriene by antagonists
MX9400204A (es) Composicion farmaceutica para reducir los niveles del factor reumatoide.